Ultrasound contrast agent developer Sonus Pharmaceuticals reported $3 million in net income for the fourth quarter of 1999 (end-December), due primarily to a second $5 million licensing payment from Nycomed Amersham. Bothell, WA-based Sonus entered into
Ultrasound contrast agent developer Sonus Pharmaceuticals reported $3 million in net income for the fourth quarter of 1999 (end-December), due primarily to a second $5 million licensing payment from Nycomed Amersham. Bothell, WA-based Sonus entered into a $10 million patent cross-licensing agreement with Nycomed last September (SCAN 10/13/99). That agreement helped Sonus year-end results considerably as well; the company reported revenues of $12 million for 1999, compared to $5 million in 1998. Net income for the year was $400,000, compared to a net loss of $11.2 million for 1998. Sonus is currently awaiting FDA clearance for EchoGen, its first ultrasound contrast agent, which the company already sells in Europe.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.